{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:44:10Z","timestamp":1794534250000,"version":"4.9.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T00:00:00Z","timestamp":1665792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T00:00:00Z","timestamp":1665792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and objective<\/jats:title>\n                <jats:p>The definition of pre-capillary pulmonary hypertension (PH) has been modified, with lowering of the mean pulmonary arterial pressure (mPAP) threshold from 25 to 20\u00a0mmHg and addition of a mandatory criterion of pulmonary vascular resistance (PVR)\u2009\u2265\u20092 Wood units (WU). Our objectives were: 1\/ to estimate the proportion of patients reclassified as having pre-capillary PH when using the new 2022 ESC\/ERS hemodynamic criteria (i.e. mPAP 21-24\u00a0mmHg and PVR\u2009\u2265\u20092 WU), and to describe their clinical characteristics and outcome; and 2\/ to study the relationship between PVR and survival in patients with mPAP\u2009&gt;\u200920\u00a0mmHg.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively analyzed consecutive SSc patients included in our National Reference Center for a first right-heart catheterization between 2003 and 2018. The association between survival and PVR was studied using smoothing splines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 126 SSc patients with mPAP\u2009&gt;\u200920\u00a0mmHg. Among them, 16 (13%) had a baseline mPAP value between 21 and 24\u00a0mmHg and PVR\u2009\u2265\u20092\u00a0mmHg and were reclassified as pre-capillary PH; 10 of which (62%) raised their mPAP\u2009\u2265\u200925\u00a0mmHg during follow-up. In patients with mPAP\u2009&gt;\u200920\u00a0mmHg, we observed a linear relation between PVR and mortality for values\u2009&lt;\u20096 WU.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A significant proportion of SSc patients is reclassified as having pre-capillary PH with the new 2022 ESC\/ERS hemodynamic definition. Lowering the PVR threshold from 3 to 2 WU captures patients at risk of raising their mPAP\u2009&gt;\u200925\u00a0mmHg, with a possibly less severe disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-022-02205-4","type":"journal-article","created":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T12:03:09Z","timestamp":1665835389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Mild pulmonary hemodynamic alterations in patients with systemic sclerosis: relevance of the new 2022 ESC\/ERS definition of pulmonary hypertension and impact on mortality"],"prefix":"10.1186","volume":"23","author":[{"given":"S\u00e9bastien","family":"Puigrenier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Giovannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Lamblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"De Groote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Fertin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Bervar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Lamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Edm\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Balquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sobanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Sanges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,15]]},"reference":[{"issue":"2","key":"2205_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11926-015-0560-x","volume":"18","author":"V Sobanski","year":"2016","unstructured":"Sobanski V, Launay D, Hachulla E, Humbert M. Current approaches to the treatment of systemic-sclerosis-associated pulmonary arterial hypertension (SSc-PAH). Curr Rheumatol Rep. 2016;18(2):10.","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"2205_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8 N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67\u2013119.","journal-title":"Eur Heart J"},{"issue":"10","key":"2205_CR3","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall AJ, Bannert B, Vonk M, Air\u00f2 P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809\u201315.","journal-title":"Ann Rheum Dis"},{"key":"2205_CR4","first-page":"7","volume":"89","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart J. 2022;89:7.","journal-title":"European Heart J"},{"issue":"2","key":"2205_CR5","doi-asserted-by":"publisher","first-page":"1900586","DOI":"10.1183\/13993003.00586-2019","volume":"54","author":"S Jaafar","year":"2019","unstructured":"Jaafar S, Visovatti S, Young A, Huang S, Cronin P, Vummidi D, et al. Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis. Eur Respir J. 2019;54(2):1900586.","journal-title":"Eur Respir J"},{"issue":"3","key":"2205_CR6","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/annrheumdis-2019-216476","volume":"79","author":"P Xanthouli","year":"2020","unstructured":"Xanthouli P, Jordan S, Milde N, Marra A, Blank N, Egenlauf B, et al. Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. Ann Rheum Dis. 2020;79(3):370\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2205_CR7","first-page":"30","volume":"25","author":"A Sar\u0131","year":"2021","unstructured":"Sar\u0131 A, \u015eener YZ, Arma\u011fan B, K\u0131l\u0131\u00e7 L, Kaya EB, Hekimsoy V, et al. How did the updated hemodynamic definitions affect the frequency of pulmonary hypertension in patients with systemic sclerosis. Anatol J Cardiol. 2021;25(1):30\u20135.","journal-title":"Anatol J Cardiol"},{"key":"2205_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/13993003.01913-2018","volume":"53","author":"G Simonneau","year":"2019","unstructured":"Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1.","journal-title":"Eur Respir J"},{"issue":"11","key":"2205_CR9","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. Classification Criteria for Systemic Sclerosis: An ACR-EULAR Collaborative Initiative. Arthritis Rheum. 2013;65(11):2737\u201347.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2205_CR10","doi-asserted-by":"publisher","first-page":"1801897","DOI":"10.1183\/13993003.01897-2018","volume":"53","author":"J Vachi\u00e9ry","year":"2019","unstructured":"Vachi\u00e9ry J, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, et al. Pulmonary hypertension due to left heart disease. Eur Respir J. 2019;53(1):1801897.","journal-title":"Eur Respir J"},{"issue":"4","key":"2205_CR11","doi-asserted-by":"publisher","first-page":"1701197","DOI":"10.1183\/13993003.01197-2017","volume":"51","author":"JG Coghlan","year":"2018","unstructured":"Coghlan JG, Wolf M, Distler O, Denton CP, Doelberg M, Harutyunova S, et al. Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. Eur Respir J. 2018;51(4):1701197.","journal-title":"Eur Respir J"},{"issue":"13","key":"2205_CR12","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1161\/CIRCULATIONAHA.115.020207","volume":"133","author":"BA Maron","year":"2016","unstructured":"Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, et al. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the veterans affairs clinical assessment, reporting, and tracking program. Circulation. 2016;133(13):1240\u20138.","journal-title":"Circulation"},{"key":"2205_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13075-019-1981-0","volume":"21","author":"Z Pan","year":"2019","unstructured":"Pan Z, Marra AM, Benjamin N, et al. Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). Arthritis Res Ther. 2019;21:217.","journal-title":"Arthritis Res Ther"},{"key":"2205_CR14","first-page":"34","volume":"67","author":"BA Maron","year":"2022","unstructured":"Maron BA, Brittain EL, Hess E, Waldo SW, Bar\u00f3n AE, Huang S, et al. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet. 2022;67:34.","journal-title":"Lancet"},{"key":"2205_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12890-021-01623-2","volume":"21","author":"K Yamamoto","year":"2021","unstructured":"Yamamoto K, Tanabe N, Takahashi Y, Naito A, Sekine A, Suda R, et al. Characteristics of patients meeting the new definition of pre-capillary pulmonary hypertension (Nice 2018) in a single Japanese pulmonary hypertension center. BMC Pulm Med. 2021;21:1.","journal-title":"BMC Pulm Med"},{"issue":"10","key":"2205_CR16","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/thx.2008.112847","volume":"64","author":"TJ Corte","year":"2009","unstructured":"Corte TJ, Wort SJ, Gatzoulis MA, Macdonald P, Hansell DM, Wells AU. Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax. 2009;64(10):883\u20138.","journal-title":"Thorax"},{"issue":"3","key":"2205_CR17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/acr.22121","volume":"66","author":"L Chung","year":"2014","unstructured":"Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, et al. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken). 2014;66(3):489\u201395.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"2205_CR18","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1002\/art.38029","volume":"65","author":"G Lef\u00e8vre","year":"2013","unstructured":"Lef\u00e8vre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M, et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum. 2013;65(9):2412\u201323.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2205_CR19","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1002\/art.22069","volume":"54","author":"MR Fisher","year":"2006","unstructured":"Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 2006;54(9):3043\u201350.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2205_CR20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.chest.2017.02.010","volume":"152","author":"S Ramjug","year":"2017","unstructured":"Ramjug S, Hussain N, Hurdman J, Billings C, Charalampopoulos A, Elliot CA, et al. Idiopathic and systemic sclerosis-associated pulmonary arterial hypertension: a comparison of demographic, hemodynamic, and mri characteristics and outcomes. Chest. 2017;152(1):92\u2013102.","journal-title":"Chest"},{"issue":"1","key":"2205_CR21","doi-asserted-by":"publisher","first-page":"1901654","DOI":"10.1183\/13993003.01654-2019","volume":"56","author":"S Ratwatte","year":"2020","unstructured":"Ratwatte S, Anderson J, Strange G, Corrigan C, Collins N, Celermajer DS, et al. Pulmonary arterial hypertension with below threshold pulmonary vascular resistance. Eur Respir J. 2020;56(1):1901654.","journal-title":"Eur Respir J"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02205-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-022-02205-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02205-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,16]],"date-time":"2022-10-16T00:04:11Z","timestamp":1665878651000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-022-02205-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,15]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2205"],"URL":"https:\/\/doi.org\/10.1186\/s12931-022-02205-4","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,15]]},"assertion":[{"value":"9 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complied with the recommendations of the Helsinki declaration. French legislation on noninterventional studies does not require ethics committee approval for the use of de-identified data collected during patient care. The data were de-identified and complied with the requirements of the \u201c<i>Commission Nationale de l\u2019Informatique et des Libert\u00e9s<\/i>\u201d (CNIL), the organization responsible for ensuring the ethical use of data collected for scientific purposes in France. The CNIL approved the methods used to collect and analyze data from our patient database (approval #DEC18-445).French legislation on noninterventional studies requires collecting the non-opposition of patients but does not require written consent. As such, non-opposition was obtained from each patient included in the study for the use of their de-identified medical record data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SS reports travel grants from Shire, Sanofi-Genzyme, SOBI and Novartis; consulting fees from Novartis. DL reports research support from Actelion, GSK, and Pfizer; Octapharma, Takeda, Biocryst, CSL Behring. NL reported personal fees from Actelion (Janssen), Akcea, Alnylam, Amicus therapeutics, Bayer, Novartis, MSD, Pfizer, Sanofi-Aventis, and travel grants from Amgen and Bristol-Myers Squibb. PDG reports fees from Novartis, Servier, Astra-Zeneca, Abbott, Vifor, Janssen, Boehringer Ingelheim, Bayer, MSD. JFB reports travel grants from Pfizer, MSD, Janssen, AstraZeneca, Novartis Pharma France, and Chiesi; and board participation fees from Novartis Pharma France. EH reports consulting fees from Actelion, Boehringer Ingelheim, GSK, Roche-Chugai, Sanofi-Genzyme; speaking fees from Actelion, GSK, Roche-Chugai; and research funding from CSL Behring, GSK, Roche-Chugai.SP, JG, MF, AL, JLE, MHB and VS did not report any conflict of interest related to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"284"}}